Context

HighLife is a medtech company focused on Transcatheter Mitral Valve Replacement (TMVR) for treating mitral regurgitation.

HighLife develops a minimally invasive prosthetic mitral valve implanted on a beating heart through the femoral vein and artery while preserving the native valve structure and respecting the surrounding anatomy.

Recognized as being best-in-class, the valve can be delivered trans-septally via the femoral vein in a reversible manner. The trans-septal route is the preferred route for both interventionists and patients as it avoids any surgery.

One of the few trans-septal valves in clinical development, HighLife competes with large international medtech companies and its technology offers differentiating features, notably: ease of use, self-centering and broad-fitting.

HighLife needed to raise funds to finance a US feasibility study and pivotal CE-marking study until 2021.

About Highlife

HighLife SAS was established in 2010 and is headquartered in Paris, France, with offices in Irvine (California). It is focused on the development of a novel transcatheter replacement system for treating mitral regurgitation. The technology aims at a beating heart procedure reducing trauma to the patients.

Discover Highlife

Olivier Garnier

Investment Banking

Romain Ellul

Investment Banking

Sandrine Cailleteau

Investment Banking

Remi Negre

Investment Banking

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center